JP2009538607A5 - - Google Patents

Download PDF

Info

Publication number
JP2009538607A5
JP2009538607A5 JP2009512510A JP2009512510A JP2009538607A5 JP 2009538607 A5 JP2009538607 A5 JP 2009538607A5 JP 2009512510 A JP2009512510 A JP 2009512510A JP 2009512510 A JP2009512510 A JP 2009512510A JP 2009538607 A5 JP2009538607 A5 JP 2009538607A5
Authority
JP
Japan
Prior art keywords
responder
ccl5
patient
immunotherapy
sample
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009512510A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009538607A (ja
Filing date
Publication date
Priority claimed from GB0610949A external-priority patent/GB0610949D0/en
Priority claimed from GB0700761A external-priority patent/GB0700761D0/en
Application filed filed Critical
Priority claimed from PCT/EP2007/004915 external-priority patent/WO2007140958A2/en
Publication of JP2009538607A publication Critical patent/JP2009538607A/ja
Publication of JP2009538607A5 publication Critical patent/JP2009538607A5/ja
Pending legal-status Critical Current

Links

JP2009512510A 2006-06-02 2007-05-31 患者が免疫療法に対する応答者であるかどうかを同定する方法 Pending JP2009538607A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0610949A GB0610949D0 (en) 2006-06-02 2006-06-02 Method
GB0700761A GB0700761D0 (en) 2007-01-15 2007-01-15 Method
PCT/EP2007/004915 WO2007140958A2 (en) 2006-06-02 2007-05-31 Method for identifying whether a patient will be responder or not to immunotherapy

Publications (2)

Publication Number Publication Date
JP2009538607A JP2009538607A (ja) 2009-11-12
JP2009538607A5 true JP2009538607A5 (https=) 2010-07-08

Family

ID=38801855

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009512510A Pending JP2009538607A (ja) 2006-06-02 2007-05-31 患者が免疫療法に対する応答者であるかどうかを同定する方法

Country Status (15)

Country Link
US (1) US20100021424A1 (https=)
EP (23) EP2390360A1 (https=)
JP (1) JP2009538607A (https=)
KR (1) KR20090017655A (https=)
AR (1) AR061136A1 (https=)
AU (1) AU2007256383B2 (https=)
BR (1) BRPI0712497A2 (https=)
CA (1) CA2653949A1 (https=)
CL (1) CL2007001571A1 (https=)
EA (1) EA200802242A1 (https=)
ES (1) ES2539042T3 (https=)
MX (1) MX2008015372A (https=)
PE (1) PE20080742A1 (https=)
TW (1) TW200817680A (https=)
WO (1) WO2007140958A2 (https=)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2227558A1 (en) * 2007-11-30 2010-09-15 GlaxoSmithKline Biologicals SA Method for classifying cancer patients as responder or non-responder to immunotherapy
GB0816867D0 (en) * 2008-09-15 2008-10-22 Glaxosmithkline Biolog Sa Method
GB2466025A (en) * 2008-12-08 2010-06-09 Univ Francois Rabelais De Tour C3/ITGAM polymorphisms and cancer prognosis
GB0917457D0 (en) * 2009-10-06 2009-11-18 Glaxosmithkline Biolog Sa Method
WO2011084333A1 (en) * 2009-12-16 2011-07-14 Hitachi Chemical Co., Ltd. Method for characterizing host immune function by ex vivo induction of offensive and defensive immune markers
EP2380991A1 (en) 2010-04-20 2011-10-26 Universitätsklinikum Hamburg-Eppendorf Method of determining the metastatic potential of a tumor
EP2619574B1 (en) * 2010-09-15 2020-10-28 Almac Diagnostic Services Limited Molecular test for predicting responsiveness to dna-damage therapeutic agents in individuals having cancer
KR101287600B1 (ko) * 2011-01-04 2013-07-18 주식회사 젠큐릭스 초기유방암의 예후 예측용 유전자 및 이를 이용한 초기유방암의 예후예측 방법
CN103987861A (zh) 2011-10-14 2014-08-13 加州大学评议会 皮肤鳞状细胞癌和假性上皮瘤样增生的基于多重pcr的测试及其区分方法
EP2872646B1 (en) * 2012-07-12 2017-08-30 Institut National de la Sante et de la Recherche Medicale (INSERM) Methods for predicting the survival time and treatment responsiveness of a patient suffering from a solid cancer with a signature of at least 7 genes
JO3519B1 (ar) 2013-01-25 2020-07-05 Amgen Inc تركيبات أجسام مضادة لأجل cdh19 و cd3
WO2015077717A1 (en) 2013-11-25 2015-05-28 The Broad Institute Inc. Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status
WO2015085147A1 (en) 2013-12-05 2015-06-11 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
KR20230076867A (ko) 2013-12-20 2023-05-31 더 브로드 인스티튜트, 인코퍼레이티드 신생항원 백신과의 병용 요법
US20170202478A1 (en) * 2014-07-03 2017-07-20 University Of Virginia Patent Foundation Systems and methods for identifying and profiling muscle patterns
WO2016049276A1 (en) * 2014-09-25 2016-03-31 Moffitt Genetics Corporation Prognostic tumor biomarkers
US10975442B2 (en) 2014-12-19 2021-04-13 Massachusetts Institute Of Technology Molecular biomarkers for cancer immunotherapy
EP3234130B1 (en) 2014-12-19 2020-11-25 The Broad Institute, Inc. Methods for profiling the t-cell- receptor repertoire
JP6489900B2 (ja) * 2015-03-30 2019-03-27 株式会社ジャパンディスプレイ 入力装置及び表示装置
IL294183B2 (en) 2015-05-20 2023-10-01 Dana Farber Cancer Inst Inc shared neoantigens
CA2992282A1 (en) * 2015-07-14 2017-01-19 Atossa Genetics Inc. Transpapillary methods and compositions for treating breast disorders
DE112016003948T5 (de) 2015-08-31 2018-05-09 City Of Sapporo Molekulare verfahren zum beurteilen einer urothelialen erkrankung
US11549149B2 (en) 2017-01-24 2023-01-10 The Broad Institute, Inc. Compositions and methods for detecting a mutant variant of a polynucleotide
CA3058807A1 (en) 2017-04-03 2018-10-11 Biontech Us Inc. Protein antigens and uses thereof
TW201930340A (zh) 2017-12-18 2019-08-01 美商尼恩醫療公司 新抗原及其用途
MX2020014243A (es) 2018-06-19 2021-05-12 Biontech Us Inc Neoantigenos y usos de los mismos.
GB201908565D0 (en) * 2019-06-14 2019-07-31 Cray Innovation Ab Method of stratifying subjects into sub-groups for therapeutic treatment
CN114540504B (zh) * 2022-04-27 2022-07-08 广州万德基因医学科技有限公司 用于预测肺鳞癌患者免疫疗效的标志物组及系统

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR1001034B (el) * 1989-07-21 1993-03-31 Ortho Pharma Corp Μεθοδος διεγερσης του πολλαπλασιασμου λεμφοκυτταρων περιφερειακου αιματος.
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
CA2138997C (en) 1992-06-25 2003-06-03 Jean-Paul Prieels Vaccine composition containing adjuvants
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
EP1167379A3 (en) 1994-07-15 2004-09-08 University Of Iowa Research Foundation Immunomodulatory oligonucleotides
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US6303347B1 (en) 1997-05-08 2001-10-16 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
CZ298364B6 (cs) 1998-02-05 2007-09-05 Smithkline Beecham Biologicals S. A. Deriváty antigenu asociovaných s nádory z MAGE rodiny a sekvence nukleových kyselin kodující tyto deriváty, jejich použití pro prípravu fúzních proteinu a prostredku pro vakcinaci
PT1104306E (pt) 1998-08-10 2006-05-31 Antigenics Inc Composicoes de cpg e adjuvantes de saponina e seus metodos
CZ20012587A3 (cs) 1999-01-29 2002-05-15 Corixa Corporation Izolovaný protein, nukleová kyselina, virový vektor, farmaceutický prostředek, izolovaná populace T buněk, způsob posílení imunitní odpovědi, způsob odstranění nádorových buněk, způsob stimulace a/nebo namnoľení T buněk a způsob přípravy fúzního proteinu
PT1165778E (pt) 1999-03-11 2007-01-31 Glaxosmithkline Biolog Sa Utilizações de polinucleótidos e polipéptidos casb618
PT1187629E (pt) 1999-04-19 2005-02-28 Glaxosmithkline Biolog Sa Composicao adjuvante que compreende saponina e um oligonucleotido imunoestimulador
IL151097A0 (en) 2000-02-23 2003-04-10 Smithkline Beecham Biolog Tumour-specific animal proteins
AUPR077900A0 (en) * 2000-10-13 2000-11-09 Tvw Telethon Institute For Child Health Research Immunodiagnosis
US20020076469A1 (en) * 2000-10-31 2002-06-20 Colgate-Palmolive Company Composition and method
WO2002068614A2 (en) * 2001-02-26 2002-09-06 Gesellschaft Fuer Biotechnologische Forschung Mbh (Gbf) Interferon regulatory factor-1/human estrogen receptor fusion protein and its use for treating carcinomas
WO2002076469A1 (en) * 2001-03-27 2002-10-03 Baylor College Of Medicine A novel technology of intracellular delivery of dna oligonucleotides to improve drug activity
DE10127572A1 (de) * 2001-05-30 2002-12-05 Pathoarray Gmbh Werkzeuge zur Diagnostik, molekularen Definition und Therapieentwicklung chronischer entzündlicher Gelenkerkrankungen
US7229774B2 (en) * 2001-08-02 2007-06-12 Regents Of The University Of Michigan Expression profile of prostate cancer
JP4424987B2 (ja) * 2001-09-20 2010-03-03 ボード オブ リージェンツ， ザ ユニバーシティ オブ テキサス システム Ｅｌｉｓａアッセイを用いた循環する治療抗体、抗原および抗原／抗体複合体の測定
WO2003050257A2 (en) * 2001-12-06 2003-06-19 University Of Florida Targeting leukemia cells
DE60234386D1 (de) 2002-02-04 2009-12-24 Corixa Corp Neue immuneffektor-verbindungen
US20040248151A1 (en) * 2002-04-05 2004-12-09 Ventana Medical Systems, Inc. Method for predicting the response to HER2-directed therapy
KR20050010040A (ko) 2002-06-11 2005-01-26 글락소스미스클라인 바이오로지칼즈 에스.에이. 면역원성 조성물
US20040231909A1 (en) * 2003-01-15 2004-11-25 Tai-Yang Luh Motorized vehicle having forward and backward differential structure
WO2004076565A2 (en) * 2003-02-25 2004-09-10 Technical Knockout, Inc. Improved coated weight plates, dumbbells and method of manufacture
US20040191819A1 (en) * 2003-02-28 2004-09-30 Bayer Pharmaceuticals Corporation Expression profiles for breast cancer and methods of use
US20050095607A1 (en) * 2003-03-07 2005-05-05 Arcturus Bioscience, Inc. University Of Louisville Breast cancer signatures
WO2004081564A1 (en) 2003-03-14 2004-09-23 Peter Maccallum Cancer Institute Expression profiling of tumours
US20040241725A1 (en) * 2003-03-25 2004-12-02 Wenming Xiao Lung cancer detection
US7598287B2 (en) * 2003-04-01 2009-10-06 Medical College Of Georgia Research Institute, Inc. Use of inhibitors of indoleamine-2,3-dioxygenase in combination with other therapeutic modalities
US7640114B2 (en) * 2003-05-21 2009-12-29 The Wistar Institute Of Anatomy & Biology Method of diagnosis of cancer based on gene expression profiles in cells
AU2004248120B2 (en) * 2003-05-28 2009-04-23 Genomic Health, Inc. Gene expression markers for predicting response to chemotherapy
CA2527680A1 (en) 2003-05-30 2005-06-02 Astrazeneca Uk Limited Markers for responsiveness to an erbb receptor tyrosine kinase inhibitor
WO2005001138A2 (en) * 2003-06-18 2005-01-06 Arcturus Bioscience, Inc. Breast cancer survival and recurrence
WO2005001117A1 (ja) * 2003-06-27 2005-01-06 Haruo Sugiyama Ｗｔ１ワクチン適応患者の選択方法
ATE403755T1 (de) * 2003-08-28 2008-08-15 Ipsogen Identifizierung einer erbb2- genexpressionssignatur bei brustkrebs
WO2005032495A2 (en) 2003-10-03 2005-04-14 Bayer Pharmaceuticals Corporation Gene expression profiles and methods of use
US20070110710A1 (en) * 2003-11-05 2007-05-17 New England Medical Center Hospitals, Inc. Treatment with immunoregulatory t cells
WO2005054496A1 (ja) * 2003-12-02 2005-06-16 Orient Cancer Therapy Co., Ltd. 細胞動態の検査方法
WO2005059543A1 (en) * 2003-12-12 2005-06-30 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g protein-coupled receptor h963 (h963)
EP1721991B1 (en) * 2004-02-09 2015-09-30 Fuso Pharmaceutical Industries Ltd. Method of detecting nucleic acid and utilization thereof
US20060195266A1 (en) 2005-02-25 2006-08-31 Yeatman Timothy J Methods for predicting cancer outcome and gene signatures for use therein
US7332281B2 (en) * 2004-04-27 2008-02-19 Sagres Discovery, Inc. Therapeutic targets in cancer
EP1782070B1 (en) * 2004-06-17 2010-09-08 MannKind Corporation Tumor-associated antigen profiles in cancer diagnostics and immunotherapy
US8053197B2 (en) * 2004-07-30 2011-11-08 Oregon Health & Science University Methods for detecting and treating autoimmune disorders
CA2587676A1 (en) 2004-11-19 2006-05-26 Institut Gustave Roussy Improved treatment of cancer by double-stranded rna
US20060110371A1 (en) * 2004-11-23 2006-05-25 Institut Pasteur Control of indoleamine 2,3 deoxygenase expression and activity
CA2589782A1 (en) 2004-11-30 2006-06-08 Veridex Llc Lung cancer prognostics
US20070059720A9 (en) * 2004-12-06 2007-03-15 Suzanne Fuqua RNA expression profile predicting response to tamoxifen in breast cancer patients
WO2006073982A2 (en) * 2004-12-30 2006-07-13 Regents Of The University Of California Bispecific molecule comprising ligands for cell-surface protein and t-cell surface protein
US7666595B2 (en) 2005-02-25 2010-02-23 The Brigham And Women's Hospital, Inc. Biomarkers for predicting prostate cancer progression
GB0504302D0 (en) 2005-03-02 2005-04-06 Univ Dublin Markers for melanoma
WO2006103442A2 (en) 2005-04-01 2006-10-05 Ncc Technology Ventures Pte. Ltd. Materials and methods relating to breast cancer classification
CA2604844A1 (en) * 2005-04-07 2006-10-19 Novartis Vaccines And Diagnostics, Inc. Cancer-related genes
CA2604852A1 (en) * 2005-04-15 2006-10-26 Oncomethylome Sciences, S.A. Methylation markers for diagnosis and treatment of cancers
CA2608359A1 (en) 2005-05-13 2006-11-23 Duke University Gene expression signatures for oncogenic pathway deregulation
US20070111257A1 (en) * 2005-07-07 2007-05-17 Kohne David E Improved protein expression comparison assay results and applications
CN101283275A (zh) * 2005-10-11 2008-10-08 默克专利有限公司 趋化因子表达的依赖egfr的调控和对肿瘤的诊断和治疗的影响及其副作用
EP1777523A1 (en) * 2005-10-19 2007-04-25 INSERM (Institut National de la Santé et de la Recherche Médicale) An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method

Similar Documents

Publication Publication Date Title
JP2009538607A5 (https=)
Bonne et al. Salivary biomarker development using genomic, proteomic and metabolomic approaches
JP2020028300A5 (https=)
Payne et al. Circulating tumor DNA as a biomarker and liquid biopsy in head and neck squamous cell carcinoma
WO2014140933A8 (en) Method for the prognosis and treatment of cancer metastasis
GB2488700B (en) Methods for monitoring disease conditions by analysis of the full repertoire of CDR3 sequences of an individual
EA201070863A1 (ru) Способы детекции признаков заболеваний или состояний в жидкостях организма
EA201792497A1 (ru) Антитела к gitr для диагностики злокачественной опухоли
EP1810026A4 (en) B7-H1 AND METHOD FOR THE DIAGNOSIS, FORECAST AND TREATMENT OF CANCER
JP2013066474A5 (https=)
WO2011103236A3 (en) Personalized tumor biomarkers
JP2016500110A5 (https=)
WO2012047899A3 (en) Novel dna hypermethylation diagnostic biomarkers for colorectal cancer
WO2008091814A3 (en) Assessment of asthma and allergen-dependent gene expression
WO2012177945A3 (en) Diagnostic methods for eosinophilic esophagitis
WO2010027903A3 (en) Lung cancer diagnosis
MX2013006669A (es) Conjunto de sondas de oligonucleotido y metodos para perfilado de microbiotica.
JP2014144959A5 (https=)
Leung et al. Ovarian cancer biomarkers: current state and future implications from high-throughput technologies
NZ578283A (en) Proteomic profiling method useful for condition diagnosis and monitoring, composition screening, and therapeutic monitoring
EP3159695A3 (en) Methods for diagnosing pancreatic cancer
WO2015052583A3 (en) Method for the prognosis and treatment of metastasizing cancer of the bone originating from breast cancer
WO2010028373A3 (en) Methods for diagnosing cancer and determining the overall survival and disease-free survival of cancer patients
WO2007146668A3 (en) Use of imp3 as a prognostic marker for cancer
JP2019527361A5 (https=)